Israel Cancer Research Fund Unveils New $5.35 Million Grants for Innovative Cancer Research
The Israel Cancer Research Fund (ICRF) has recently unveiled its commitment of $5.35 million in grants dedicated to cancer research for the 2026 to 2027 fiscal year. This substantial investment aims to support 38 innovative projects spearheaded by leading scientists in Israel.
These new grants are a testament to ICRF's ongoing support for cancer research, raising its lifetime investment to nearly $109 million since its inception in 1975, which has funded over 3,000 cancer research grants. ICRF's contribution has significantly advanced cancer research and patient care worldwide. In total, with an additional 57 renewing grants, ICRF will facilitate 95 active research grants during the upcoming funding year, amounting to an impressive $5.84 million in collaborative funding.
Alan Herman, the Executive Director of ICRF, emphasized that each grant represents a crucial investment in the scientists and their groundbreaking ideas that hold the potential to reshape cancer science for future generations. "We take pride in supporting Israel's exceptional scientific community, from budding researchers to established leaders, helping turn bold concepts into pivotal discoveries that can enhance patient lives across the globe," he stated.
The new grants encompass a diverse range of cancer research areas, reflecting Israel's dynamic scientific landscape. Recipients are exploring avant-garde methodologies in artificial intelligence, advanced imaging techniques, liquid biopsy technology, genomics, microbiome studies, as well as innovations in immunotherapy and precision medicine.
Among the noteworthy projects receiving funding this year include:
1. Lucio Frydman, PhD, Weizmann Institute of Science: Frydman was awarded a Research Professorship Grant for his project on "Integrated Metabolic and Microstructural MRI for Early Cancer Detection." This project aims to develop non-intrusive methods for the early identification of cancer using sophisticated MRI technology, integrating metabolic and structural imaging to highlight high-risk lesions, potentially negating the need for invasive biopsies.
2. Irit Ben Aharon, MD, PhD, Rambam Health Care Campus: This recipient of a Research Professorship Grant is investigating the effects of chemotherapy during pregnancy. Her research focuses on how treatment impacts both mother and fetus, examining various clinical challenges and identifying long-term effects of in utero exposure.
3. Liran Shlush, MD, PhD, Weizmann Institute of Science: With a Project Grant, Shlush is developing a novel single-cell analysis approach for diagnosing acute leukemias through a minimally invasive liquid biopsy technique. This innovative method seeks to decrease the necessity for frequent bone marrow biopsies while ensuring precise analysis and diagnosis.
4. Asael Roichman, PhD, Bar Ilan University: Awarded a Career Development Award, Roichman is researching the interactions between diet, microbiome, and cancer drug efficacy. His findings aim to contribute to personalized treatment plans that account for individual patient responses to therapy.
The selection of projects for ICRF funding is governed by a stringent peer-review process akin to that of the National Institutes of Health (NIH), ensuring that grants are awarded based on scientific merit, originality, and potential to propel cancer research forward.
ICRF not only supports seasoned scientists but also nurtures emerging researchers through its three core grant categories: Career Development Awards, Project Grants, and Research Professorships. Over the past five decades, ICRF-funded scientists have made groundbreaking discoveries, including pivotal research on DNA methylation, BRCA mutations, and the advent of targeted therapies like immunotherapy.
As it moves forward into the next generation of cancer research, ICRF remains steadfast in its mission to fund bold, innovative ideas that hold the promise of transforming cancer care on a global scale. By investing in the talents and creativity of Israeli scientists, ICRF is dedicated to enhancing the lives of cancer patients around the world.
These new grants are a testament to ICRF's ongoing support for cancer research, raising its lifetime investment to nearly $109 million since its inception in 1975, which has funded over 3,000 cancer research grants. ICRF's contribution has significantly advanced cancer research and patient care worldwide. In total, with an additional 57 renewing grants, ICRF will facilitate 95 active research grants during the upcoming funding year, amounting to an impressive $5.84 million in collaborative funding.
Alan Herman, the Executive Director of ICRF, emphasized that each grant represents a crucial investment in the scientists and their groundbreaking ideas that hold the potential to reshape cancer science for future generations. "We take pride in supporting Israel's exceptional scientific community, from budding researchers to established leaders, helping turn bold concepts into pivotal discoveries that can enhance patient lives across the globe," he stated.
The new grants encompass a diverse range of cancer research areas, reflecting Israel's dynamic scientific landscape. Recipients are exploring avant-garde methodologies in artificial intelligence, advanced imaging techniques, liquid biopsy technology, genomics, microbiome studies, as well as innovations in immunotherapy and precision medicine.
Among the noteworthy projects receiving funding this year include:
1. Lucio Frydman, PhD, Weizmann Institute of Science: Frydman was awarded a Research Professorship Grant for his project on "Integrated Metabolic and Microstructural MRI for Early Cancer Detection." This project aims to develop non-intrusive methods for the early identification of cancer using sophisticated MRI technology, integrating metabolic and structural imaging to highlight high-risk lesions, potentially negating the need for invasive biopsies.
2. Irit Ben Aharon, MD, PhD, Rambam Health Care Campus: This recipient of a Research Professorship Grant is investigating the effects of chemotherapy during pregnancy. Her research focuses on how treatment impacts both mother and fetus, examining various clinical challenges and identifying long-term effects of in utero exposure.
3. Liran Shlush, MD, PhD, Weizmann Institute of Science: With a Project Grant, Shlush is developing a novel single-cell analysis approach for diagnosing acute leukemias through a minimally invasive liquid biopsy technique. This innovative method seeks to decrease the necessity for frequent bone marrow biopsies while ensuring precise analysis and diagnosis.
4. Asael Roichman, PhD, Bar Ilan University: Awarded a Career Development Award, Roichman is researching the interactions between diet, microbiome, and cancer drug efficacy. His findings aim to contribute to personalized treatment plans that account for individual patient responses to therapy.
The selection of projects for ICRF funding is governed by a stringent peer-review process akin to that of the National Institutes of Health (NIH), ensuring that grants are awarded based on scientific merit, originality, and potential to propel cancer research forward.
ICRF not only supports seasoned scientists but also nurtures emerging researchers through its three core grant categories: Career Development Awards, Project Grants, and Research Professorships. Over the past five decades, ICRF-funded scientists have made groundbreaking discoveries, including pivotal research on DNA methylation, BRCA mutations, and the advent of targeted therapies like immunotherapy.
As it moves forward into the next generation of cancer research, ICRF remains steadfast in its mission to fund bold, innovative ideas that hold the promise of transforming cancer care on a global scale. By investing in the talents and creativity of Israeli scientists, ICRF is dedicated to enhancing the lives of cancer patients around the world.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.